Paper413551
In vitro studies with hexamethylmelamine.
Rutty CJ and 1 other. Biochem Pharmacol, 1977. Cited by 82 papers, by iCite.
Cite this record
ConductScience Library. In vitro studies with hexamethylmelamine. Papers, record 413551. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/413551
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Altretamine | Major topic |
| Triazines | Major topic |
| Animals | |
| Antineoplastic Agents | |
| Chromatography, Thin Layer | |
| Dealkylation | |
| Female | |
| In Vitro Techniques | |
| Mice | |
| Mice, Inbred BALB C | |
| Microsomes, Liver | |
| Rats | |
| Structure-Activity Relationship |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 82 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7656502 | Clinical pharmacokinetics of altretamine. | Clin Pharmacokinet | 1995 | https://conductscience.org/library/papers/7656502 | PubMed |
| 7641606 | Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. | Drugs | 1995 | https://conductscience.org/library/papers/7641606 | PubMed |
| 7272193 | British Association for Cancer Research 22nd Annual general meeting. 13-15 April 1981. Abstracts. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7272193 | PubMed |
| 7126433 | The British Association for Cancer Research, 23rd annual general meeting. Edinburgh 29--31 March 1982. Abstracts. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7126433 | PubMed |
| 6994913 | The practical benefits of pharmacokinetics in the use of antineoplastic agents. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/6994913 | PubMed |
| 6808457 | Hexamethylmelamine and hexamethylmelamine hydrochloride. | Pharm Weekbl Sci | 1982 | https://conductscience.org/library/papers/6808457 | PubMed |
| 6807560 | The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6807560 | PubMed |
| 6794923 | Dose-dependent pharmacokinetics of PMM in the rat. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/6794923 | PubMed |
| 6791675 | In vitro sensitivity of human ovarian tumours to chemotherapeutic agents. | Br J Cancer | 1981 | https://conductscience.org/library/papers/6791675 | PubMed |
| 6770884 | Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites. | Br J Cancer | 1980 | https://conductscience.org/library/papers/6770884 | PubMed |
| 6432969 | Human central nervous system pharmacology of pentamethylmelamine and its metabolites. | J Neurooncol | 1983 | https://conductscience.org/library/papers/6432969 | PubMed |
| 6401427 | Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6401427 | PubMed |
| 3924426 | Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/3924426 | PubMed |
| 3552281 | N-methyl antitumour agents. A distinct class of anticancer drugs? | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3552281 | PubMed |
| 3100080 | Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3100080 | PubMed |
| 3091280 | Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3091280 | PubMed |
| 3087399 | Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3087399 | PubMed |
| 1997112 | Phase II trial of trimelamol in refractory ovarian cancer. | Br J Cancer | 1991 | https://conductscience.org/library/papers/1997112 | PubMed |
| 508562 | Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. | Br J Cancer | 1979 | https://conductscience.org/library/papers/508562 | PubMed |
| 475962 | Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour. | Br J Cancer | 1979 | https://conductscience.org/library/papers/475962 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/413551
GET https://conductscience.org/api/papers/v1/413551/cited_by?page=2